News Incyte Corporation

Equities

INCY

US45337C1027

Real-time Estimate Cboe BZX Other stock markets 01:39:40 2024-04-19 pm EDT			5-day change	1st Jan Change
52.5 ^USD	-0.61%		-2.58%	-16.45%

02:45pm	BMO Capital Adjusts Price Target on Incyte to $56 From $64	MT
Apr. 01	Incyte, China Medical System Sign Collaboration, License Agreement	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Adjusts Price Target on Incyte to $56 From $64	08:45am	MT
Incyte to Report First Quarter Financial Results	Apr. 11	BU
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(4) - March 29, 2024	Apr. 01	AQ
Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	BU
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 29	BU
Trial of Insider Trading Case Against Former Medivation Employee Begins in California	Mar. 26	MT
SEC v Panuwat: The SEC's Novel "Shadow Trading" Insider Trading Case Goes To Trial	Mar. 19	AQ
Incyte's Povorcitinib Potentially Suited for Hidradenitis Suppurativa, Prurigo Nodularis, RBC Says	Mar. 12	MT
Transcript : Incyte Corporation - Shareholder/Analyst Call	Mar. 11
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis	Mar. 10	BU
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa	Mar. 10	BU
Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)	Mar. 10	CI
New Data from Incyte's Growing Dermatology Portfolio to Be Presented At the 2024 American Academy Of Dermatology Annual Meeting	Mar. 05	AQ
Transcript : Incyte Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:50 AM	Mar. 04
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting	Mar. 04	BU
Wall Street: a flurry of records, including that of the Nasdaq 'broad	Mar. 01	CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'.	Feb. 29	CF
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI	Feb. 29	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Incyte Corporation : Is a big change imminent?

October 26, 2023 at 10:00 am EDT